eFFECTOR Therapeutics IPO

eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs).

Register for Details

For more details on financing and valuation of private companies similar to eFFECTOR Therapeutics before its SPAC, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about eFFECTOR Therapeutics

To invest in eFFECTOR Therapeutics pre-IPO

Can you invest in eFFECTOR Therapeutics pre-IPO?

You may invest in eFFECTOR Therapeutics as it is a public company listed on the NASDAQ with ticker EFTR. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of eFFECTOR Therapeutics before it goes public?

You can no longer sell shares of eFFECTOR Therapeutics on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my eFFECTOR Therapeutics shares?

Forge can no longer determine the value of eFFECTOR Therapeutics shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is eFFECTOR Therapeutics a publicly traded company?

eFFECTOR Therapeutics became a public company following its SPAC on 08/26/2021 and is now traded on the NASDAQ under the ticker EFTR.

To learn more about eFFECTOR Therapeutics potential IPO

Will eFFECTOR Therapeutics go IPO?

eFFECTOR Therapeutics became a public company following its SPAC on 08/26/2021 and is now traded on the NASDAQ under the ticker EFTR.

What is eFFECTOR Therapeutics’ IPO price?

The IPO price of eFFECTOR Therapeutics is not currently available.

When was eFFECTOR Therapeutics founded?

eFFECTOR Therapeutics was founded in 2012.

What is eFFECTOR Therapeutics funding to date?

eFFECTOR Therapeutics has raised $152.08MM to date.

eFFECTOR Therapeutics Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
08/24/2017 Series C $39.1MM $xx.xx $197.73MM Pfizer Venture Investments, Alexandria Venture Investments, U.S. Venture Partners, Abingworth, Novartis Venture Fund, SR One, The Column Group, Altitude Life Science Ventures, Sectoral Asset Management, Abbvie Biotech Ventures, BioMed Ventures, Astellas Ventures
Price per Share
$xx.xx
Shares Outstanding
76,070,076
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Pfizer Venture Investments, Alexandria Venture Investments, U.S. Venture Partners, Abingworth, Novartis Venture Fund, SR One, The Column Group, Altitude Life Science Ventures, Sectoral Asset Management, Abbvie Biotech Ventures, BioMed Ventures, Astellas Ventures
12/22/2015 Series B $56MM $xx.xx $141.22MM Altitude Life Science Ventures, AbbVie Biotech Ventures, BioMed Ventures, Abingworth, Novartis Venture Fund, SR One, The Column Group, US Venture Partners, Astellas Ventures, Osage University Partners, Mission Bay Capital
Price per Share
$xx.xx
Shares Outstanding
114,646,041
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Altitude Life Science Ventures, AbbVie Biotech Ventures, BioMed Ventures, Abingworth, Novartis Venture Fund, SR One, The Column Group, US Venture Partners, Astellas Ventures, Osage University Partners, Mission Bay Capital
05/20/2013 Series A $56.98MM $xx.xx $67.04MM SR One, Novartis Venture Funds, Astellas Venture Management, Abingworth, Osage University Partners, U.S. Venture Partners, Mission Bay Capital
Price per Share
$xx.xx
Shares Outstanding
145,560,097
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
11.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
SR One, Novartis Venture Funds, Astellas Venture Management, Abingworth, Osage University Partners, U.S. Venture Partners, Mission Bay Capital
Updated on: Nov 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.